Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Michael

Showing results (1041-1050 of 1,306) with videos related to

Pageof 131
Sort By:
Heart Rhythm|June 7, 2008
Risk of death in the long QT syndrome when a sibling has diedElizabeth S Kaufman, Scott McNitt, Arthur J Moss, et al.
Circulation|September 4, 2019
Comparison of a Complete Percutaneous Versus Surgical Approach to Aortic Valve Replacement and Revascularization in Patients at Intermediate Surgical Risk: Results From the Randomized SURTAVI TrialLars Søndergaard, Jeffrey J Popma, Michael J Reardon, et al.
Circulation|April 28, 2017
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart AssociationSheryl L Chow, Alan S Maisel, Inder Anand, et al.
European Heart Journal|May 2, 2017
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)Peter S Pang, Javed Butler, Sean P Collins, et al.
Heart Rhythm|March 15, 2011
Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndromeAlon Barsheshet, Derick R Peterson, Arthur J Moss, et al.
International Journal of Cardiology|January 8, 2018
Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHFMarco Metra, Beth A Davison, Claudio Gimpelewicz, et al.
Biorxiv : the Preprint Server for Biology|February 16, 2022
A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19Jonathan H Shrimp, John Janiszewski, Catherine Z Chen, et al.
JACC. Heart Failure|April 28, 2023
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT TrialMuhammad Shahzeb Khan, Sumitabh Singh, Matthew W Segar, et al.
JACC. Heart Failure|February 5, 2015
Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)G Michael Felker, Javed Butler, Sean P Collins, et al.
The American Journal of Cardiology|July 30, 2020
Propensity-Matched Comparison of Evolut-R Transcatheter Aortic Valve Implantation With Surgery in Intermediate-Risk Patients (from the SURTAVI Trial)Steven J Yakubov, Nicolas M Van Mieghem, Michael J Reardon, et al.
Pageof 131

Showing results (1041-1050 of 1,306) with videos related to

Sort By:
Pageof 131
Heart Rhythm|June 7, 2008
Risk of death in the long QT syndrome when a sibling has diedElizabeth S Kaufman, Scott McNitt, Arthur J Moss, et al.
Circulation|September 4, 2019
Comparison of a Complete Percutaneous Versus Surgical Approach to Aortic Valve Replacement and Revascularization in Patients at Intermediate Surgical Risk: Results From the Randomized SURTAVI TrialLars Søndergaard, Jeffrey J Popma, Michael J Reardon, et al.
Circulation|April 28, 2017
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart AssociationSheryl L Chow, Alan S Maisel, Inder Anand, et al.
European Heart Journal|May 2, 2017
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)Peter S Pang, Javed Butler, Sean P Collins, et al.
Heart Rhythm|March 15, 2011
Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndromeAlon Barsheshet, Derick R Peterson, Arthur J Moss, et al.
International Journal of Cardiology|January 8, 2018
Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHFMarco Metra, Beth A Davison, Claudio Gimpelewicz, et al.
Biorxiv : the Preprint Server for Biology|February 16, 2022
A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19Jonathan H Shrimp, John Janiszewski, Catherine Z Chen, et al.
JACC. Heart Failure|April 28, 2023
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT TrialMuhammad Shahzeb Khan, Sumitabh Singh, Matthew W Segar, et al.
JACC. Heart Failure|February 5, 2015
Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)G Michael Felker, Javed Butler, Sean P Collins, et al.
The American Journal of Cardiology|July 30, 2020
Propensity-Matched Comparison of Evolut-R Transcatheter Aortic Valve Implantation With Surgery in Intermediate-Risk Patients (from the SURTAVI Trial)Steven J Yakubov, Nicolas M Van Mieghem, Michael J Reardon, et al.
Pageof 131